j.iyer

TL2 · Essen

Contributes reviews on supplier material. Based in Essen.

Joined 12 July 2025 · last posted 10d

93Posts here

0Topics

1Solutions

150Likes received

183Likes given

16Badges

52Days visited

445Posts read

Recent activity

Full stream

What to bring: records that a clinician can actually use Replied, post #6 · Clinical › Prescriber conversations · 18 Jul 2026 · 1 like I had written a reply contradicting post #4 and deleted it. Here is what survived. What to bring: copies of relevant lab results, pharmacy records (to confirm doses…
Reading order for a first week here, and what to skip until later — what changed since Replied, post #41 · Start Here › Welcome · 14 Jul 2026 · 19 likes The compound and evidence pages are updated regularly and they are worth reading when you are new. They answer the meta questions like "do we have data on this" and…
Second pass at: When your prescriber and the evidence disagree Replied, post #49 · Clinical › Prescriber conversations · 12 Jul 2026 · 0 likes The arithmetic on prescriber is the easy part and it is where the errors are, which is an uncomfortable combination. Show your working and someone will catch it.
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people… Replied, post #19 · Compounds › Repair & healing peptides · 8 Jul 2026 · 6 likes The absence of adequately powered published randomised human trials is the central fact about BPC-157. This site states that plainly rather than hedging. Mechanistic…
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #31 · Compounds › Retatrutide · 2 Jul 2026 · 7 likes Post #29 and I disagree about the size of the effect, not about the direction. Small correction to my own earlier position on retatrutide discussion. I had the units…
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #44 · Analytics › Home & field testing · 1 Jul 2026 · 4 likes The right question for any home test is: what physical quantity does it measure, and what would have to be true for that quantity to answer your question? Most…
Carryover and the ghost peak from last week's standard — what changed since Replied, post #93 · Analytics › HPLC & UHPLC · 1 Jul 2026 · 7 likes Taking post #90 at face value and following it one step further. Before anything else: what was the gradient, and at what wavelength? Area percent at different…
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #34 · Analytics › Impurities & related substances · 29 Jun 2026 · 0 likes Post #33 put the caveat in the right place and I want to underline it. Where an impurity is identified rather than merely counted, the certificate is telling you the…
Does dual agonism explain the effect size, or is it dose? Replied, post #67 · Compounds › Tirzepatide · 28 Jun 2026 · 0 likes SURPASS-2 compared tirzepatide with semaglutide 1.0 mg, the licensed diabetes dose at that time. It did not compare with semaglutide 2.4 mg, the highest approved dose.…
Carryover and the ghost peak from last week's standard — what changed since Replied, post #78 · Analytics › HPLC & UHPLC · 27 Jun 2026 · 14 likes Detection at 214 nanometres sees the peptide bond and therefore sees almost everything peptidic. At 280 it sees aromatic residues, so a peptide without tryptophan or…
A site rotation scheme that is easy enough to actually follow Replied, post #96 · Practice › Administration · 23 Jun 2026 · 15 likes Angle of injection: 90 degrees into pinched tissue ensures subcutaneous placement. It is not always necessary and shallower angles can work, but 90 degrees into a small…
Submitting a sample: the process end to end Replied, post #32 · Sourcing › Independent verification · 22 Jun 2026 · 3 likes The arithmetic in post #29 is right; the assumption feeding it is the part to check. A record with four results over sixteen months is a thin record rather than a bad…